Figure 6.

Cell cycle control in human Wharton’s jelly mesenchymal stem cells (hWJ-MSCs) after a 24 h-Cytochalasin B (CB) treatment. (a) Cell cycle analysis was assessed by flow cytometry in hWJ-MSCs treated with CB 1 μM, dimethyl sulfoxide (DMSO) 0.05% (CB vehicle), or without treatment (CTR) for 24 h. The quantification of hWJ-MSCs in each cell cycle phase gate (G1/G0, S, and G2/M) is presented as percentage of cells. (b) The expression of MKI67 (Proliferation marker protein Ki-67), CCND1 (cyclin D1), CDKN1A (cyclin dependent kinase inhibitor 1A), CDKN2A (cyclin dependent kinase inhibitor 2A) and OCT-4 (Octamer-binding transcription factor 4) genes was assessed in hWJ-MSCs treated with CB 1 μM, DMSO, or without treatment (CTR) for 24 h. Data were normalized using three housekeeping genes (glyceraldehyde 3-phosphate dehydrogenase—GAPDH, TATA box binding protein—TBP and tyrosine 3 monooxygenase/tryptophan 5-monooxygenase activation protein zeta—YWHAZ); the normalized expression value of CTR was set up to 1, and all other gene expression values were reported to that sample. Data are reported as normalized fold change ± standard deviation (SD); n = 3. Black columns refer to CTR cells, blue columns refer to DMSO-treated cells, yellow columns refer to CB-treated cells. * p < 0.05 and ** p < 0.01 vs. CTR.